No known drug interactions for the matched ingredients — not a guarantee none exist. Check your meds →
Dietary supplement

UritraX Ingredients & Drug Interactions

by XYMOGEN

Liquid Category: Fiber And Other Nutrients
No known interaction
The interaction bottom line No known interaction

UritraX is a dietary supplement by XYMOGEN with 1 active ingredient. Its ingredients are commonly taken for preventing urinary tract infections (utis), treating mild utis, urinary tract health.We don’t currently list a known drug interaction for its mapped ingredients — but that doesn’t guarantee none exist, so always confirm with your pharmacist.

Computed from our clinical databases

HelloPharmacist Scorecard of UritraX by XYMOGEN

Four independent checks of what is known — a summary of the available information, not a grade of the product itself.

Evidence for Intended Use
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not assessable

The stated purpose hasn't been mapped to our evidence data yet.

Why this rating?
  • We haven't mapped this product's purpose to our evidence data yet — it'll be graded on the next content refresh.
Ingredient Transparency
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 1 of its 1 active ingredient.
  • No proprietary blends here — you can verify the dose of every single component.
Known Interaction Concern
No known interactions

No medication interactions are currently documented for the matched ingredients — that isn't a guarantee none exist.

Why this rating?
  • None of the 1 matched ingredient has a documented medication interaction on file.
Safety Information
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

HelloPharmacist summaryFully disclosed formula with no assessable stated purpose. No medication interactions are currently documented, and safety information is well characterized.

Assessment coverage: 1 of 1 active ingredient matched to our full ingredient reviews (monographs). Based on the product label dated Mar 23, 2012.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about UritraX, straight from the product label.

Brand XYMOGEN
Net contents 1.76 oz.; 50 g
Market status Off market
Date entered into DSLD Mar 23, 2012
DSLD ID 6121
Product type Fiber And Other Nutrients
Supplement form Liquid
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegan, Vegetarian, Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for UritraX by XYMOGEN, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
0.5 tsp
Maximum serving Sizes:
0.5 tsp
Servings per container
50
IngredientAmount% DV
D-Mannose0.9 g--

Other ingredients: None

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
FDA Statement of Identity

Dietary Supplement

Suggested/Recommended/Usage/Directions

DIRECTIONS: Mix one-half teaspoon in 2-4 oz water one to three times daily, or as directed by your healthcare practitioner

Precautions

Keep out of reach of children.

• Pharmaceutical Grade • Professional Use Only

Avoid if allergic to any ingredient.

CAUTIONS: Consult your healthcare practitioner before use.

FDA Disclaimer Statement

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Storage

STORAGE: Keep tightly closed in a cool, dry place.

General Statements

Concentrated Urinary Tract Support

Featuring D-Mannose

This package is completely recyclable (recycle)

EXCLUSIVE PROFESSIONAL FORMULAS

General

TC# E4350501 REV. 120611

Brand IP Statement(s)

XYMOGEN 2011

All XYMOGEN(R) Formulas Meet or Exceed cGMP Quality Standards.

UritraX(TM) features D-mannose, a simple sugar that occurs naturally in cranberries and pineapple. Research suggests that D-mannose interferes with adhesion of E coli to the bladder wall, thereby supporting a healthy urinary tract.*

Formulation

DOES NOT CONTAIN: Wheat, gluten, corn protein, yeast, soy, animal or dairy products, artificial colors, artificial sweeteners, or preservatives.

See for yourself

UritraX by XYMOGEN label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in UritraX by XYMOGEN

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size0.5 tsp Dosage formLiquid Servings per container50 Amounts shown are per serving.

D-Mannose

No known
interactions
0.9 g per serving

D-mannose is a natural sugar most often used to help prevent urinary tract infections, especially those caused by E. coli. Early research is promising...

D-Mannose monograph & interactions

Other (inactive) ingredients: None. These complete the product’s ingredient list but are not active constituents.

Interaction report

UritraX by XYMOGEN Drug Interactions

We don’t currently list any known drug interactions for the mapped ingredients in UritraX. This doesn’t guarantee none exist — always confirm with your pharmacist before combining a supplement with your medications.

The maker

Brand information

Manufacturer and brand details for UritraX, from the product label.

XYMOGEN

See all XYMOGEN products
Name
XYMOGEN Exclusive Professional Formulas
Street Address
725 S. Kirkman Rd.
City
Orlando
State
FL
ZipCode
32811
Phone Number
800-647-6100
Web Address
www.xymogen.com
Pharmacist Counseling Corner

UritraX by XYMOGEN: Common Questions

Does UritraX by XYMOGEN interact with any medications?
We do not currently list a known interaction for the mapped ingredients in UritraX. This does not guarantee none exist, so confirm with your pharmacist.
How can one product interact with so many drugs?
UritraX contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if UritraX is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

UritraX label
Go deeper

The Full Monographs Behind UritraX’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Sources

Sources & How We Checked

UritraX's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 6 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

D-mannose 6 references
  1. Westphal V, Kjaergaard S, Davis JA, et al. Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation. Mol Genet Metab 2001;73:77-85. PubMed
  2. Kranjcec B, Papes D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79-84.
  3. de Lonlay P, Seta N. The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochim Biophys Acta. 2009;1792(9):841-3. PubMed
  4. Harms HK, Zimmer KP, Kurnik K, Bertele-Harms RM, Weidinger S, Reiter K. Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr. 2002;91(10):1065-72. DOI
  5. . Damen G, de Klerk H, Huijmans J, den Hollander J, Sinaasappel M. Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic. J Pediatr Gastroenterol Nutr. 2004;38(3):282-7. DOI
  6. Lenger SM, Bradley MS, Thomas DA, Bertolet MH, Lowder JL, Sutcliffe S. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;223(2):265.e1-265.e13. PubMed

See these in context on the D-mannose monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring